Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension

Elias A Sanidas; Dimitrios P Papadopoulos; Erifili Hatziagelaki; Charalampos Grassos; Maria Velliou; John Barbetseas

doi:10.1093/ajh/hpz157

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension

Am J Hypertens. 2020 Mar 13;33(3):207-213. doi: 10.1093/ajh/hpz157.

Authors

Elias A Sanidas¹, Dimitrios P Papadopoulos¹, Erifili Hatziagelaki², Charalampos Grassos³, Maria Velliou¹, John Barbetseas¹

Affiliations

¹ Hypertension Excellence Centre-ESH, Department of Cardiology, LAIKO General Hospital, Athens, Greece.
² 2nd Department of Internal Medicine, Attikon General Hospital, Athens Medical School, Athens, Greece.
³ Hypertension Excellence Centre-ESH, Department of Cardiology, KAT General Hospital, Athens, Greece.

PMID: 31541572
DOI: 10.1093/ajh/hpz157

Abstract

Sodium glucose cotransporter 2 (SGLT2) inhibitors represent a novel class of oral antihyperglycemic drugs that have been approved over the last decade for the management of type 2 diabetes mellitus. Except the glucose-lowering effects, robust evidence also suggests that SGLT2 inhibitors confer benefits in cardiovascular system. The purpose of this review was to investigate the effects of SGLT2 inhibitors across the spectrum of arterial hypertension.

Keywords: SGLT-2 inhibitors; arterial hypertension; blood pressure; diabetes mellitus.

Publication types

Review

MeSH terms

Animals
Antihypertensive Agents / therapeutic use*
Arterial Pressure / drug effects*
Humans
Hypertension / diagnosis
Hypertension / drug therapy*
Hypertension / physiopathology
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Treatment Outcome

Substances

Antihypertensive Agents
Sodium-Glucose Transporter 2 Inhibitors